.jpeg)
2026-06-25 06:31:57
Tildrakizumab is a humanized monoclonal antibody targeting the IL-23 p19 subunit. This article reviews its efficacy in achieving high skin clearance rates (PASI 90/100), its favorable safety profile, convenient dosing schedule, and specific limitations regarding psoriatic arthritis and live vaccines.
2026-06-24 04:56:11
Olutasidenib is an oral selective IDH1 inhibitor approved for adult patients with relapsed or refractory acute myeloid leukemia harboring IDH1 mutations. This article covers its mechanism of action, indications, clinical efficacy data and global treatment options.
2026-06-24 04:44:34
Lusutrombopag is an oral medication indicated for thrombocytopenia in patients with chronic liver disease prior to elective invasive procedures. This guide covers standard dosage, dose adjustment, missed dose management, monitoring protocols and special population considerations.
2026-06-24 04:39:21
Gilteritinib (brand name XOSPATA) is a second-generation, highly selective FLT3 inhibitor indicated for relapsed or refractory FLT3-mutated acute myeloid leukemia. This article provides a comprehensive review of its mechanism of action, key clinical data, global access options, adverse event management and cutting-edge research progress.
2026-06-23 06:15:37
This article reviews clinical response patterns of margetuximab combined with chemotherapy for HER2-positive metastatic breast cancer, based on the Phase 3 SOPHIA trial. It details median time to response, RECIST evaluation cycles, key efficacy data, and factors influencing therapeutic outcomes.
2026-06-22 06:48:58
Brensocatib is an oral dipeptidyl peptidase-1 (DPP1) inhibitor indicated for neutrophil-mediated inflammatory diseases such as non-cystic fibrosis bronchiectasis. This article covers pre-treatment assessments, monitoring protocols, drug interactions and dosing recommendations for special populations.
2026-06-17 07:33:39
This article outlines the main adverse reaction profiles of gilteritinib, a FLT3-targeted therapy, and analyzes its safety characteristics and clinical monitoring principles from the dimensions of hematologic toxicity, organ safety risks and special differentiation syndrome.
2026-06-16 04:56:11
This article introduces the mechanism of action, clinical benefits and safety profile of lemborexant, a novel DORA-class sleep medication, compares its mechanistic differences from traditional sedative-hypnotics, and analyzes its value in insomnia management.
2026-06-16 04:42:47
This article analyzes the adverse reaction characteristics of idelalisib, a selective PI3Kδ inhibitor, describes its safety risks across digestive, respiratory, cutaneous, hematological and hepatic dimensions, and introduces internationally accepted clinical monitoring and management principles.
2026-06-16 04:31:29
This article presents the eligible population, mechanism of action and clinical positioning of the avutometinib + defactinib combination regimen, and elaborates its clinical value and prerequisite for use in precision treatment of low-grade serous ovarian cancer.
2026-06-16 04:16:36
This article illustrates the action pathways, eligible patient groups and medication characteristics of pemafibrate in triglyceride reduction, and analyzes its role and benefits in the treatment of lipid metabolic disorders.
2026-06-12 02:58:34
This article provides a detailed overview of the results from a multicenter phase 1 clinical trial of Ceralasertib, an ATR kinase inhibitor, in combination with Durvalumab (brand name Imfinzi), a PD-L1 inhibitor, for the treatment of recurrent or metastatic non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC). It covers study design, mechanism of action, efficacy data, safety assessment, and the recommended phase 2 dosing regimen, serving as a reference for patients and healthcare professionals on cutting-edge cancer treatments.
